Peer-reviewed veterinary case report
Rifampicin treatment results and side effects in 104 dogs with MRSP
By Lu, Tian Chee et al.·Published in Veterinary dermatology·2026·Animal Skin and Ear Specialists, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of Meticillin-Resistant Staphylococcus Pyoderma With Rifampicin in 104 Dogs: Clinical Outcomes, Adverse Effects, and Rifampicin Resistance in Nonresponders.
- Species:
- dog
Plain-English summary
A group of 104 dogs with a skin infection caused by a tough-to-treat bacteria called MRSP (meticillin-resistant Staphylococcus pseudintermedius) were treated with an antibiotic called rifampicin for 21 days. Most dogs showed improvement, with 82.7% responding well to the treatment. However, some dogs developed resistance to the antibiotic, which means it may not work for them in the future. While most dogs tolerated the treatment well, a small number experienced side effects, and combining rifampicin with other medications could increase the risk of severe reactions. Overall, rifampicin can be effective for this type of skin infection, but pet owners should be aware of the potential for resistance and side effects.
People also search for: dog skin infection treatment · MRSP pyoderma antibiotic · rifampicin side effects in dogs
Abstract
BACKGROUND: Meticillin-resistant Staphylococcus pseudintermedius (MRSP) is often resistant to multiple antibiotics. Rifampicin is effective against most MRSP isolates, yet the potential for the development of rapid resistance raises questions regarding its suitability as an antibiotic monotherapy for MRSP pyoderma. OBJECTIVES: To describe the: (i) clinical outcome of rifampicin antibiotic monotherapy in MRSP pyoderma; (ii) frequency of adverse effects; and (iii) development of rifampicin resistance among dogs considered nonresponders to therapy. MATERIALS AND METHODS: A retrospective study of medical records from 1/1/2013 to 1/12/2022 of client-owned dogs with MRSP pyoderma treated with oral rifampicin as a systemic antibiotic monotherapy for 21 days. RESULTS: 104 dogs were included; 77 cases of superficial pyoderma (74%) and 27 cases of deep pyoderma (26%). The mean daily rifampicin dose was 6 mg/kg. Rifampicin was clinically effective in 86 cases (82.7%). Eleven of 18 nonresponding dogs demonstrated rapidly acquired rifampicin resistance (10.6%). Eighty-two (78.8%), 17 (16.3%), two (1.9%) and three (2.9%) dogs experienced zero, mild, moderate and severe adverse effects, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: Rifampicin at 6 mg/kg is an effective and mostly well-tolerated monotherapy for treating MRSP pyoderma. However, in this study, it was associated with rapid development of resistance in ≥ 10% of treated dogs. Inadequate clinical response occurred without demonstrable resistance in 6.7% of cases. Concurrent use of ciclosporin or fluconazole with rifampicin increased the odds of severe adverse reactions.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41147707/